Is setmelanotide a GLP-1 drug?

No. It targets the melanocortin-4 receptor, an entirely different mechanism from the incretins.

Patients with rare genetic obesity caused by defects in the MC4R pathway — a defined and narrow population.

What did VENTURE show?

It was a one-year open-label Phase 3 trial extending setmelanotide use to children aged 2 to 5 with MC4R pathway-associated obesity.

GLP-1 & Incretin Science

The Obesity Drug That Is Not an Incretin

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Setmelanotide is a melanocortin-4 receptor agonist approved for rare genetic obesity caused by defects in the MC4R pathway. It works through an entirely different mechanism from the incretins, and its VENTURE Phase 3 trial extended use to children aged 2 to 5.

Key facts

Target: Melanocortin-4 receptor (MC4R)
Not: A GLP-1 or incretin agonist
Indication: Rare MC4R pathway-associated obesity
VENTURE trial: Phase 3, ages 2–5, 1 year, open-label
Published: Lancet Diabetes Endocrinol 2025 (PMID 39549719)
Related receptor family: MC1R to MC5R

A different pathway entirely

The incretin drugs act on GLP-1, GIP and glucagon receptors. Setmelanotide acts on the melanocortin-4 receptor, part of a five-member family whose members sit in different tissues — MC1R on melanocytes driving pigmentation, MC2R in the adrenal cortex, MC3R and MC4R centrally in energy balance.

Why MC4R is a genuine obesity target

The melanocortin pathway is a central regulator of energy balance, and defects in it cause severe early-onset obesity. That is not a hypothesis — it is a defined genetic mechanism with identified patients, which is why an agonist for it could be developed for a specific indication rather than for obesity in general.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What VENTURE reported

Argente and colleagues published a one-year, open-label, multicentre Phase 3 trial of setmelanotide in patients aged 2 to 5 with rare MC4R pathway-associated obesity in the Lancet Diabetes and Endocrinology in January 2025. Extending an approved medicine into very young children with a defined genetic condition is a narrow and specific development step.

Why it is not a competitor to the incretins

Different populations entirely. Setmelanotide addresses rare monogenic obesity in identified patients; the incretins address common polygenic obesity in very large populations. They are both obesity medicines in the way that two drugs for different cancers are both oncology medicines — the category is shared and little else is.

The melanocortin connection elsewhere in this catalogue

MC4R belongs to the same receptor family this site describes in its MT-2 articles. Alpha-MSH and its derivatives act across that family, and selectivity between members is the central design problem. Setmelanotide is what a deliberately selective, regulator-assessed melanocortin agonist looks like — which is a useful contrast with compounds described as non-selective.

Regulatory position and what is not implied

Setmelanotide is a licensed medicine for a specific rare indication, prescribed and monitored clinically. Nothing supplied as research material is related to it, and no melanocortin research compound is an alternative to it or covered by its approval.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is setmelanotide a GLP-1 drug?: No. It targets the melanocortin-4 receptor, an entirely different mechanism from the incretins.
Who is it for?: Patients with rare genetic obesity caused by defects in the MC4R pathway — a defined and narrow population.
What did VENTURE show?: It was a one-year open-label Phase 3 trial extending setmelanotide use to children aged 2 to 5 with MC4R pathway-associated obesity.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum